BioPharmSignal logoBioPharmSignal

Biotech News

Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs

Jaguar Health (JAGX)Jaguar HealthCompany update

Global Market for Short Bowel Syndrome, Including Intestinal Failure (IF), Estimated to Reach $8.0 Billion by 2033 1 AI data mining of real world clinical and symptom manifestation is beneficial in the development of credible links between genetics, histopathology, and disease progression

Related news

JAGXJaguar Health2026-06-12 13:00 EST

Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases

JAGXJaguar Health2026-09-10 13:00 EST

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

SCYXSCYNEXIS2026-10-22 12:00 EST

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases

SCYXSCYNEXIS2026-09-28 11:30 EST

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

VIRXViracta Therapeutics2024-11-06 20:19 EST

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

IBRXImmunityBio2026-10-14 20:18 EST

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

HROWHarrow, Inc.2026-08-06 11:00 EST

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

IBRXImmunityBio2026-07-29 22:45 EST

ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

ALZNAlzamend Neuro2025-07-23 12:00 EST

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

HROWHarrow, Inc.2026-07-20 11:00 EST

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

View all latest news

Jaguar Health

Plant-Derived Gastrointestinal Medicines Jaguar Health develops prescription medicines derived from plants for serious gastrointestinal disorders. Its Napo subsidiaries lead development and commercialization of crofelemer for rare intestinal-failure conditions. Crofelemer Mechanism Crofelemer is a plant-derived antisecretory medicine...

Recent company news

JAGXJaguar Health2026-11-06 21:15 EST

Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders

JAGXJaguar Health2026-11-02 14:00 EST

CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)

JAGXJaguar Health2026-10-21 13:00 EST

Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder

JAGXJaguar Health2026-10-14 20:15 EST

Jaguar Health Provides Update Regarding Special Stock Dividend

JAGXJaguar Health2026-10-14 13:00 EST

Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer

Stock data

Close
0.41 USD
Market cap
2.12M USD
Exchange
NASDAQ
Sector
Biopharma
Location
San Francisco, California